CR20220008A - Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de citocinas - Google Patents
Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de citocinasInfo
- Publication number
- CR20220008A CR20220008A CR20220008A CR20220008A CR20220008A CR 20220008 A CR20220008 A CR 20220008A CR 20220008 A CR20220008 A CR 20220008A CR 20220008 A CR20220008 A CR 20220008A CR 20220008 A CR20220008 A CR 20220008A
- Authority
- CR
- Costa Rica
- Prior art keywords
- binding molecule
- cell antigen
- antibody
- combination
- cytokine inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Abstract
La presente descripción proporciona una terapia de combinación que usa una molécula de unión al antígeno anticélulas T junto con un inhibidor de citocina. Un anticuerpo que moviliza las células T como células efectoras hacia un tejido tumoral se denomina anticuerpo de redireccionamiento de células T y se conoce como un medio para tratar tumores. Sin embargo, desde otro punto de vista, cuando la unión de un anticuerpo a las células T estimula la producción de citocinas sistémicas, se teme que la función sistémica dé lugar a algunos problemas tales como el SRC. La presente descripción proporciona un medio para suprimir la producción de citocinas sistémicas y, por lo tanto, permite el uso más seguro de una molécula de unión al antígeno anti-células T en el tratamiento de tumores.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019107894 | 2019-06-10 | ||
| JP2019124364 | 2019-07-03 | ||
| PCT/JP2020/022771 WO2020250915A1 (ja) | 2019-06-10 | 2020-06-10 | サイトカイン阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220008A true CR20220008A (es) | 2022-02-11 |
Family
ID=73780894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220008A CR20220008A (es) | 2019-06-10 | 2020-06-10 | Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de citocinas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220348658A1 (es) |
| EP (1) | EP3981429A4 (es) |
| JP (2) | JP7082245B2 (es) |
| KR (2) | KR102486064B1 (es) |
| CN (1) | CN114126649A (es) |
| AU (1) | AU2020291300A1 (es) |
| CA (1) | CA3140537A1 (es) |
| CR (1) | CR20220008A (es) |
| IL (1) | IL288374A (es) |
| MA (1) | MA56131A (es) |
| MX (1) | MX2021015007A (es) |
| TW (1) | TW202112395A (es) |
| WO (1) | WO2020250915A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4319809A1 (en) * | 2021-04-06 | 2024-02-14 | Memorial Sloan Kettering Cancer Center | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer |
| WO2024083959A1 (en) * | 2022-10-20 | 2024-04-25 | Monta Biosciences Aps | Pre-medication and improved treatment regimen |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773719A (en) | 1966-12-06 | 1973-11-20 | Hoffmann La Roche | 2-aminoxy-2'-acyl-acetanilide |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
| WO2009011941A2 (en) | 2007-04-04 | 2009-01-22 | The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| BR112013013311A2 (pt) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
| TWI726842B (zh) | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | 免疫活化抗原結合分子 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| CN107556387A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用 |
| JP2020503260A (ja) * | 2016-11-15 | 2020-01-30 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
-
2020
- 2020-06-10 CN CN202080051046.XA patent/CN114126649A/zh active Pending
- 2020-06-10 AU AU2020291300A patent/AU2020291300A1/en active Pending
- 2020-06-10 KR KR1020217041104A patent/KR102486064B1/ko active IP Right Grant
- 2020-06-10 CR CR20220008A patent/CR20220008A/es unknown
- 2020-06-10 MA MA056131A patent/MA56131A/fr unknown
- 2020-06-10 CA CA3140537A patent/CA3140537A1/en active Pending
- 2020-06-10 JP JP2021526105A patent/JP7082245B2/ja active Active
- 2020-06-10 EP EP20822960.9A patent/EP3981429A4/en active Pending
- 2020-06-10 US US17/616,373 patent/US20220348658A1/en active Pending
- 2020-06-10 WO PCT/JP2020/022771 patent/WO2020250915A1/ja unknown
- 2020-06-10 TW TW109119459A patent/TW202112395A/zh unknown
- 2020-06-10 KR KR1020237000158A patent/KR20230011470A/ko active Application Filing
- 2020-06-10 MX MX2021015007A patent/MX2021015007A/es unknown
-
2021
- 2021-11-24 IL IL288374A patent/IL288374A/en unknown
-
2022
- 2022-05-26 JP JP2022085724A patent/JP2022116185A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021015007A (es) | 2022-01-31 |
| JP2022116185A (ja) | 2022-08-09 |
| JP7082245B2 (ja) | 2022-06-07 |
| KR20220019706A (ko) | 2022-02-17 |
| EP3981429A9 (en) | 2022-07-06 |
| EP3981429A1 (en) | 2022-04-13 |
| KR20230011470A (ko) | 2023-01-20 |
| WO2020250915A1 (ja) | 2020-12-17 |
| KR102486064B1 (ko) | 2023-01-06 |
| JPWO2020250915A1 (es) | 2020-12-17 |
| IL288374A (en) | 2022-01-01 |
| EP3981429A4 (en) | 2023-07-26 |
| AU2020291300A1 (en) | 2022-01-06 |
| CA3140537A1 (en) | 2020-12-17 |
| MA56131A (fr) | 2022-04-13 |
| US20220348658A1 (en) | 2022-11-03 |
| TW202112395A (zh) | 2021-04-01 |
| CN114126649A (zh) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019270624B2 (en) | Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics | |
| MX2019012038A (es) | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. | |
| WO2018026819A3 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| CY1124628T1 (el) | Συζευγματα αντισωματος-φαρμακου βασει εριβουλινης και μεθοδοι χρησεως | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| MX2021002804A (es) | Terapias de combinacion. | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| MX2019006423A (es) | Composiciones y metodos relacionados con sistemas de celulas para penetrar en tumores solidos. | |
| WO2016161410A3 (en) | Treatment of cancer using inhibitors of tgf-beta and pd-1 | |
| AU2020255712B2 (en) | Anti-PD-L1/VEGF bifunctional antibody and use thereof | |
| EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| MX2022006444A (es) | Linfocitos t activados por bite ex vivo. | |
| CR20220008A (es) | Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de citocinas | |
| EA201890801A1 (ru) | Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2 | |
| MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
| MX2020012091A (es) | Composiciones anti-cd24 y usos de las mismas. | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| MX2022000726A (es) | Anticuerpos inmunomoduladores y metodos de uso de los mismos. | |
| NZ777458A (en) | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| EA201991870A1 (ru) | Лечение рака мочевого пузыря с помощью антитела к pd-l1 |